Skip to content

PreDiction and Validation of Clinical CoursE of Coronary Artery DiSease With CT-Derived Non-Invasive HemodYnamic Phenotyping and Plaque Characterization (DESTINY Study)

Prediction and Validation of Clinical Course of Coronary Artery Disease With CT-Derived Non-Invasive Hemodynamic Phenotyping and Plaque Characterization

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04794868
Acronym
DESTINY
Enrollment
356
Registered
2021-03-12
Start date
2020-04-01
Completion date
2024-12-31
Last updated
2025-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Ischemic Heart Disease

Keywords

acute coronary syndrome, plaque characteristics, fractional flow reserve, fractional myocardial mass

Brief summary

Acute coronary syndrome (ACS) and sudden cardiac death can be the first manifestation of coronary artery disease and are the leading cause of death in the majority of the world's population. The main pathophysiology of ACS is well-known and fibrous cap thickness, presence of a lipid core, and the degree of inflammation have been proposed as the key determinants of plaque vulnerability. Previous studies using virtual histology intravascular ultrasound or optical coherence tomography showed that clinical application of this concept improved risk prediction of ACS. However, these approaches have not been widely adopted in daily practice due to relatively low positive predictive values, low prevalence of high-risk plaques and the invasive nature of diagnostic modalities. Non-invasive imaging studies with coronary computed tomography angiography (CCTA) also showed the clinical value of CCTA-derived high risk plaque characteristics (HRPC). In addition, the recent progress in CCTA and computational fluid dynamics (CFD) technologies enables simultaneous assessment of anatomical lesion severity, presence of HRPC and quantification of hemodynamic forces acting on plaques in patient-specific geometric models. As plaque rupture is a complicated biomechanical process influenced by the structure and constituents of the plaque as well as the external mechanical and hemodynamic forces acting on the plaque, a comprehensive evaluation of lesion geometry, plaque characteristics and hemodynamic parameters may enhance the identification of high-risk plaque and the prediction of ACS risk. In this regard, the current study is designed to evaluate prognostic implications of comprehensive non-invasive hemodynamic assessment using CCTA and CFD in the identification of high risk plaques that caused subsequent ACS.

Detailed description

The study population was collected from Samsung Medical Center. Target population is patients who suffered a clearly documented ACS (acute myocardial infarction \[MI\] or unstable angina with objective evidence of plaque rupture) or those who underwent significant lesion progression in angiography and treated by percutaneous coronary intervention (PCI) and had undergone CCTA from 6 months to 3 years prior to the coronary events. CCTA images were screened for plaque characteristics and CFD analysis at core laboratories in Elucid Bioimaging, Inc, MA, USA and Shanghai Institute of Cardiovascular Diseases, Shanghai, China, respectively. Lesions with diameter stenosis (DS) \> 30% based on CCTA evaluation were included analysis. The presence of conventional CCTA-HRPC (minimum lumen area\<\<4 mm2, plaque burden≥70%, low-attenuation plaque, positive remodeling, napkin-ring sign, and spotty calcification) and parameters from tissue characterization using VascuCAP software will be assessed in each lesion by an independent observer blinded to the clinical data and CFD results. The hemodynamic parameters from CFD will include 1) per-vessel FFR derived from CCTA (FFRCT); 2) change in FFRCT across the lesion (△FFRCT); 3) FFRCT pullback pressure gradient (PPG) index (FFRCT-PPG index); 4) Fractional myocardial mass (FMM) of the target stenosis. Using the occurrence of ACS or PCI for the progressed lesion as clinical endpoint, prognostic implications of CCTA-derived HRPC or hemodynamic parameters will be analyzed.

Interventions

DIAGNOSTIC_TESTCCTA-derived high risk plaque characteristics

Presence of CCTA-derived high risk plaque characteristics

DIAGNOSTIC_TESTCFD-derived hemodynamic parameters

CFD-derived hemodynamic parameters

Sponsors

Elucid Bioimaging Inc.
CollaboratorINDUSTRY
Shanghai Institute of Cardiovascular Diseases
CollaboratorOTHER
Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients who presented with ACS and underwent invasive coronary angiography with identifiable culprit lesion 2. Patients who presented with stable ischemic heart disease and underwent invasive coronary angiography for the significant epicardial coronary stenosis 3. The patients who underwent coronary CT angiography, regardless of the reason (for example, routine healthcare check-up, or evaluation for stable angina or atypical chest pain) prior to the acute event. 4. Time limit of CCTA: 6 months \ 3 years prior to the event. 5. Definition of ACS: * The patients with acute myocardial infarction should meet one of the following criteria; * Cardiac enzyme elevation and * Identified culprit lesion confirmed by invasive coronary angiography, IVUS, or OCT * The patients with unstable angina should be accompanied by the evidence of plaque rupture confirmed with invasive coronary angiography, IVUS, or OCT

Design outcomes

Primary

MeasureTime frameDescription
Acute myocardial infarction3 years after index CCTATarget vessel-related acute myocardial infarction
Revascularization3 years after index CCTATarget vessel-related revsacularization

Secondary

MeasureTime frameDescription
Target vessel failure3 years after index CCTAA composite of Cardiac death, Target vessel-related acute myocardial infarction, Target vessel-related revsacularization
All-cause death3 years after index CCTAAll-cause death
Cardiac death3 years after index CCTADeath due to cardiac cause
Major adverse cardiac and cerebral events3 years after index CCTAA composite of All-cause death, Target vessel-related acute myocardial infarction, Target vessel-related revsacularization, Cerebrovascular accident

Countries

China, South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026